- $4.05bn
- $3.45bn
- $1.11bn
Alkermes Plc expected to post earnings of 1 cent a share - Earnings Preview
Alkermes Plc expected to post earnings of 1 cent a share - Earnings Preview
Brief: Sarissa Capital Comments On Alkermes Annual Meeting
Brief: Alkermes Announces Continued Board Refreshment
Brief: Alkermes Announces Four Abstracts Accepted For Presentation At The 2022 American Society Of Clinical Oncology (Asco) Annual Meeting
Alkermes hits 6-month high as schizophrenia drug fuels Q1 beat
Alkermes Plc reports results for the quarter ended in March - Earnings Summary
Brief: Alkermes PLC Reports Q1 Revenue Of $278.5 Mln
Alkermes Plc expected to post earnings of 1 cent a share - Earnings Preview
Brief: Alkermes Commences Arbitration Related To License Agreements With Janssen Pharmaceutica
Jefferies sees promising future for Alkermes' mental disorder therapy
Brief: Alkermes Presents New Nemvaleukin Alfa Monotherapy Data At American Society Of Clinical Oncology Genitourinary Cancers Symposium
Alkermes Plc reports results for the quarter ended in December - Earnings Summary
Alkermes Plc expected to post earnings of 11 cents a share - Earnings Preview
Brief: Alkermes Announces Positive Topline Results From Enlighten-Early Phase 3B Study Of Lybalvi
Brief: Alkermes Announces Positive Topline Results From Enlighten-Early Phase 3B Study Of Lybalvi
Brief: Alkermes To Present Data On Nemvaleukin Alfa At The American Society Of Clinical Oncology Gastrointestinal Cancers Symposium
Increased The Size Of The Board To Twelve Directors And Elected Dr. Cato T. Laurencin To The Board
Brief: Alkermes Announces First Subject Dosed In Phase 1 Study Of of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders